Enrollment is now complete for a Phase 2 trial that’s assessing the safety and efficacy of oral vodobatinib (K0706), an experimental Abl inhibitor, in people with early Parkinson’s disease across 84 clinical sites in the U.S., Europe, and India. The placebo-controlled trial (NCT03655236), dubbed PROSEEK and sponsored by Sun…
A trial investigating the feasibility and impact of a novel approach for increasing regular exercise among Hispanic people with Parkinson’s disease — the ethnic group in the U.S. with the highest incidence of the neurodegenerative condition — is now recruiting participants. The aim of the new approach is boosting…
Opal, Clario’s wearable sensor device, was shown to detect early motor progression in people with Parkinson’s disease more rapidly than did standard clinical rating scales. These findings suggest that this new wearable technology may work better than conventional tests to identify patients with worsening motor symptoms. Such a…
ABBV-951 (foslevodopa/foscarbidopa) — Abbvie’s continuous infusion formulation of levodopa/carbidopa that’s administered under the skin — will now be accessible at low or no cost to people in England with advanced Parkinson’s disease whose severe motor fluctuations are no longer controlled by standard treatments. That’s according to the…
Regularly practicing the Chinese martial art tai chi may slow the progression of motor and nonmotor symptoms of Parkinson’s disease, and delay needing to increase the dosage of medication over time, a study suggests. The benefits of one-year of tai chi extended to an overall reduction in complications linked…
Blood levels of tumor necrosis factor alpha (TNF-a), an inflammatory molecule, and phosphorylated alpha-synuclein, a Parkinson’s disease biomarker, could be used to distinguish Parkinson’s patients with or without fatigue. Those findings from a recent study suggest the two markers may be  “promising biomarkers in discriminating PD [Parkinson’s disease] with…
Recent research in mice has revealed possible mechanisms by which alpha-synuclein protein is transported from blood cells in circulation to the gastrointestinal (GI) tract, where the protein is then thought to travel to the brain to drive Parkinson’s disease. Cellular carriers called extracellular vesicles (EVs) released from red blood…
The Yale School of Medicine has announced it will launch the Stephen and Denise Adams Center for Parkinson’s Disease Research, a new center dedicated to changing the way Parkinson’s disease is diagnosed and treated. It will be led by Clemens Scherzer, MD, currently the director of the APDA Center…
The Parkinson KinetiGraph (PKG), a wrist-worn device resembling a watch, offers a moderate level of measurement for tracking symptom fluctuations and medication side effects in individuals with Parkinson’s disease. That’s according to the study “Application of single wrist-wearable accelerometry for objective motor diary assessment in…
Parkinson’s UK is funding two new basic research projects at the University of Edinburgh, in Scotland, that have as their goal uncovering clues to the causes of Parkinson’s disease, with a focus on genetic involvement. According to the charity organization, such basic research provides the groundwork for understanding…
Get regular updates to your inbox.
